Ultragenyx Announces Top-Line Results from Phase 3 Study of Ace-ER in GNE Myopathy

Tuesday, August 22, 2017 1 min read

Key Takeaway: Ultragenyx Announces Top-Line Results from Phase 3 Study of Ace-ER in GNE Myopathy

Full Press Release Details

Ultragenyx Announces Top-Line Results from Phase 3 Study of Ace-ER in GNE Myopathy.